Clinical ChallengesPivotal development of TPIP is expected to be difficult, both in PAH and PH-ILD.
Competitive PressureLQDA shares are currently under pressure due to the recent positive results of a competing product, TPIP, in phase 2 trials.
Product Efficacy ConcernsSignificant questions persist regarding TPIP’s efficacy in PH-ILD, considering the life-threatening nature of the disease.